Pneumococcal vaccine conjugate 10-valent - GlaxoSmithKline

Drug Profile

Pneumococcal vaccine conjugate 10-valent - GlaxoSmithKline

Alternative Names: 10-valent pneumococcal conjugate vaccine - GlaxoSmithKline; 10-valent pneumococcal vaccine conjugate - GlaxoSmithKline; 10Pn-PD-DiT; GSK-1024850A; PHiD-CV; Pneumococcal 10-valent vaccine conjugate - GlaxoSmithKline; Streptorix™; Synflorix

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis media; Pneumococcal infections
  • Registered Pneumonia

Most Recent Events

  • 01 May 2016 GlaxoSmithKline completes a phase III trial in Pneumococcal infections (In infants, Prevention) in Bangladesh (IM) (NCT02447432)
  • 27 Jul 2015 The CHMP recommends approval for the label extension of Synflorix™ in European Union
  • 01 Jun 2015 GlaxoSmithKline completes a phase III trial in Pneumococcal infections (In Children, Prevention) in Poland and Russia (NCT01746108)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top